Drug class
Non-steroidal androgen receptor inhibitor; targeted antineoplastic
Mechanism of action
Binds androgen receptors and inhibits androgen binding, receptor nuclear translocation and androgen-receptor-mediated transcription, suppressing prostate cancer cell growth.
General use cases
- Treatment of non-metastatic castration-resistant prostate cancer (nmCRPC) in combination with androgen deprivation therapy
- Treatment of metastatic hormone-sensitive prostate cancer (mHSPC) in combination with androgen deprivation therapy and docetaxel under the applicable US product indication
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
